Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene Raises $40M in Public Offering of Shares

NEW YORK (GenomeWeb) – Trovagene said today it has closed a public offering of its common stock that brought in approximately $40.3 million in gross proceeds.

The company sold 4.6 million shares, including 600,000 shares issued when the offering's underwriters exercised their full overallotment option. The offering price was $8.75 per share, Trovagene said. The firm plans to use net proceeds for research and development, working capital, and to support other general corporate activities.

Piper Jaffray and Leerink Partners acted as joint book-running managers on the offering. Janney Montgomery Scott, Cantor Fitzgerald, and Maxim Group were the co-managers.

Trovagene priced the offering last week, saying it anticipated $35 million in gross proceeds. The company had $44 million in cash and cash equivalents as of March 31, 2015.

The firm's shares were up about 4 percent to $9.70 in afternoon trading on the Nasdaq.

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.